Investigational drug · Phase 2
KYN-5356
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cognitive Impairment Associated With Schizophrenia (CIAS).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "KYN-5356"
First trial start
2025
Aug 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KYN-5356", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cognitive Impairment Associated With Schizophrenia (CIAS)
Approved drugs for the same conditions: Schizophrenia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "KYN-5356" as an intervention, largest first.
- A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaPivotal-lookingCompleted
Kynexis B.V.Industry
NCT07191483 · 149 participants · Start Aug 27, 2025 · Primary completion Sep 9, 2026
Drug: KYN-5356 low dose; KYN-5356 Medium Dose and 1 more · For: Cognitive Impairment Associated With Schizophrenia (CIAS)
Sites: Little Rock, Arkansas; Cerritos, California; Lemon Grove, California · 15 sites in all
Kynexis B.V.Industry
NCT06225115 · 72 participants · Start Dec 21, 2023 · Primary completion Oct 7, 2024
Drug: KYN-5356; placebo · For: Cognitive Dysfunction; Schizophrenia
Sites: Glendale, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- RL-007InidascaminePhase 21 trial
Recognify Life Sciences · Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.